TY - JOUR
T1 - Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007
T2 - A population-based study
AU - Tsigrelis, Constantine
AU - Tleyjeh, Imad M.
AU - Lahr, Brian D.
AU - Nyre, Lisa M.
AU - Virk, Abinash
AU - Baddour, Larry M.
N1 - Funding Information:
Financial support. National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR30582 to the Rochester Epidemiology Project) and the Mayo Clinic Rochester Small Grants Program and Baddour Family Fund Research Grants Program. Potential conflicts of interest. All authors: no conflicts.
PY - 2008/12/1
Y1 - 2008/12/1
N2 - Background. Following the introduction of a 7-valent pneumococcal conjugate vaccine for children in 2000, there has been a decrease in the incidence of invasive pneumococcal disease among both children and adults in the United States. We evaluated the hypothesis that the case-fatality and mortality rates for invasive pneumococcal disease have also decreased since 2000. Methods. We conducted a population-based outcome study in Olmsted County, Minnesota, during the period 1995-2007 that involved patients of all ages. Results. From 1 January 1995 through 31 December 2007, a total of 180 eligible cases of invasive pneumococcal disease were identified in Olmsted County. During the 13-year study period, the overall case-fatality rate for invasive pneumococcal disease decreased from 19% (14 of 74 cases) in 1995-1999 to 5% (5 of 91 cases) in 2001-2007, an 83% decrease, after adjustment for age, sex, and Charlson comorbidity index score (P =. 003). The largest decreases in case-fatality rate were seen among adults aged ≥65 years (an 86% decrease, from 31% [9 of 29 cases] to 8% [3 of 40 cases]; P = .02) and patients with invasive pneumonia (a 78% decrease, from 22% [12 of 55 cases] to 7% [5 of 72 cases]; P = .01). The overall mortality rate for invasive pneumococcal disease decreased from 2.9 deaths per 100,000 person-years in 1995-1999 to 0.7 deaths per 100,000 person-years in 2001-2007, a 78%decrease, after adjustment for age and sex in a Poisson regression model (P = .002). Conclusions. Significant decreases in the case-fatality and mortality rates for invasive pneumococcal disease were demonstrated in the population of Olmsted County. Additional studies are needed to confirm our findings in other populations.
AB - Background. Following the introduction of a 7-valent pneumococcal conjugate vaccine for children in 2000, there has been a decrease in the incidence of invasive pneumococcal disease among both children and adults in the United States. We evaluated the hypothesis that the case-fatality and mortality rates for invasive pneumococcal disease have also decreased since 2000. Methods. We conducted a population-based outcome study in Olmsted County, Minnesota, during the period 1995-2007 that involved patients of all ages. Results. From 1 January 1995 through 31 December 2007, a total of 180 eligible cases of invasive pneumococcal disease were identified in Olmsted County. During the 13-year study period, the overall case-fatality rate for invasive pneumococcal disease decreased from 19% (14 of 74 cases) in 1995-1999 to 5% (5 of 91 cases) in 2001-2007, an 83% decrease, after adjustment for age, sex, and Charlson comorbidity index score (P =. 003). The largest decreases in case-fatality rate were seen among adults aged ≥65 years (an 86% decrease, from 31% [9 of 29 cases] to 8% [3 of 40 cases]; P = .02) and patients with invasive pneumonia (a 78% decrease, from 22% [12 of 55 cases] to 7% [5 of 72 cases]; P = .01). The overall mortality rate for invasive pneumococcal disease decreased from 2.9 deaths per 100,000 person-years in 1995-1999 to 0.7 deaths per 100,000 person-years in 2001-2007, a 78%decrease, after adjustment for age and sex in a Poisson regression model (P = .002). Conclusions. Significant decreases in the case-fatality and mortality rates for invasive pneumococcal disease were demonstrated in the population of Olmsted County. Additional studies are needed to confirm our findings in other populations.
UR - http://www.scopus.com/inward/record.url?scp=55849096245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55849096245&partnerID=8YFLogxK
U2 - 10.1086/592970
DO - 10.1086/592970
M3 - Article
C2 - 18945210
AN - SCOPUS:55849096245
SN - 1058-4838
VL - 47
SP - 1367
EP - 1371
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -